Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

US mRNA specialist Moderna (Nasdaq: MRNA) has announced that its manufacturing facility in the UK has been granted a manufacturer’s license by the Medicines and Healthcare products Regulatory Agency ...

RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

At the congress, Moderna will share findings from three oral presentations and nine poster presentations, including an e-poster. The research covers the immunogenicity and safety of its mRNA vaccines ...